Which Company Has the Best Dividend -- Johnson & Johnson, Pfizer, or Merck?

Many investors often associate the health care sector with volatile biotech stocks that can soar or plunge by double digits in a single day. However, investors shouldn't overlook the big names in the pharmaceutical field such as Johnson & Johnson (NYSE: JNJ  ) , Pfizer (NYSE: PFE  ) , and Merck (NYSE: MRK  ) , which offer stable, long-term returns and generous dividends instead of back-breaking roller-coaster thrills.

Let's discuss which of these three big pharma companies offers the best dividend and stability for more passive income investors.

Which company offers the biggest yield?
Let's first compare the trailing, forward, and five-year average annual dividend yields of these three companies.

 

Trailing Annual Dividend Yield

Forward Annual Dividend Yield

5-Year Average
Dividend Yield

Johnson & Johnson

2.9%

2.8%

3.3%

Pfizer

3.1%

3.3%

3.6%

Merck

3.1%

3.5%

4.1%

Source: Yahoo Finance, February 25.

J&J clearly trails Pfizer and Merck in this department. In addition, J&J's stock price has trailed both companies over the past five years:

JNJ Chart

Source: YCharts.

Therefore, in terms of yield and price appreciation, J&J initially looks like a weaker investment than Pfizer and Merck. However, investors should remember that J&J is the largest of these three giants -- with a market cap of $257 billion, compared to Pfizer's $207 billion and Merck's $164 billion -- and, as such, is expected to grow at a slower rate.

Which company is the most generous?
Yet a company's dividend yield is only part of the big picture. The cash payout ratio, or the percentage of a company's free cash flow, or FCF, paid back to the investors, also reveals how generous a company is toward its shareholders. Because FCF data are not yet available for all three companies, I have included information from third quarter 2012 to third quarter 2013.

MRK Cash Dividend Payout Ratio (TTM) Chart

MRK Cash Dividend Payout Ratio (TTM) data by YCharts

Pfizer's cash dividend payout ratio is the lowest among these three..

Which company has the best history of boosting its dividend?
Meanwhile, a company's history of boosting its dividend speaks volumes about its commitment toward long-term shareholders. Let's take a look at the annual dividends of these three companies over the past five fiscal years.

Fiscal Year

Johnson
& Johnson

Pfizer

Merck

2009

$1.93

$0.80

$1.52

2010

$2.11

$0.72

$1.52

2011

$2.25

$0.80

$1.52

2012

$2.40

$0.88

$1.68

2013

$2.59

$0.96

$1.72

Percent change between 2009 and 2013

34%

20%

13%

Source: Capital IQ, February 25, author's calculations.

J&J has been able to continuously increase its dividend by more than Pfizer and Merck -- mainly due to billion-dollar patent cliffs at the latter two.

Pfizer's blockbuster cholesterol drug Lipitor, which generated peak sales of $13 billion, lost patent protection in 2011. To stabilize its bottom line, Pfizer cut jobs, sold off several non-core businesses, and reduced its dividend. Merck also sustained a similar blow when its blockbuster asthma treatment Singulair, which generated peak sales of $5 billion, went off patent in 2012.

By comparison, the only significant patent expiration for J&J in the next five years is Remicade, its best-selling rheumatoid arthritis treatment, which will go off patent in Europe in 2015 and in the U.S. in 2018. However, Remicade isn't Lipitor or Singulair -- the drug only accounts for 9% of J&J's top line. Therefore, J&J is unlikely to stop its tradition of raising its dividend every year.

The Foolish bottom line
With three core businesses -- consumer health care, branded pharmaceuticals, and medical devices -- J&J is the most diversified and well-balanced choice of the three. By comparison, Merck and Pfizer are much more focused on branded pharmaceuticals, which can experience more volatility due to patent expirations and generic competition.

However, both Pfizer and Merck have controlled their bottom lines and dividends with admirable discipline in times of adversity. As a result, their investors have been handsomely rewarded for staying with them for the long term. Therefore, even though J&J is the best "set it and forget it" option for novice investors, Pfizer and Merck are also solid long-term income investments that can stomach a few bumps along the way.

Want to take a break from the volatile biotech sector with a solid long-term investment?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2852679, ~/Articles/ArticleHandler.aspx, 10/1/2014 4:28:46 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement